Neutral sphingomyelinase 2 (nSMase2) catalyzes the cleavage of sphingomyelin to phosphorylcholine and ceramide, an essential step in the formation and release of exosomes from cells that is critical for intracellular communication. Chronic increase of brain nSMase2 activity and related exosome release have been implicated in various pathological processes, including the progression of Alzheimer's disease (AD), making nSMase2 a viable therapeutic target. Recently, we identified phenyl ()-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-]pyridazin-8-yl)pyrrolidin-3-yl)carbamate , the first nSMase2 inhibitor that possesses both favorable pharmacodynamics and pharmacokinetic (PK) parameters, including substantial oral bioavailability, brain penetration, and significant inhibition of exosome release from the brain in vivo. Herein we demonstrate the efficacy of in a mouse model of AD and detail extensive structure-activity relationship (SAR) studies with 70 analogues, unveiling several that exert similar or higher activity against nSMase2 with favorable pharmacokinetic properties.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025741 | PMC |
| http://dx.doi.org/10.1021/acs.jmedchem.0c00278 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Staying sane in the membrane: neutral sphingomyelinase 2 as a master regulator of plasma membrane ceramide.
J Lipid Res
December 2024
Department of Physiology, University of Kentucky School of Medicine, Lexington, KY. Electronic address:
Quinazoline derivatives as novel bacterial sphingomyelinase enzyme inhibitors.
Bioorg Chem
December 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye. Electronic address:
Bacillus cereus sphingomyelinase C (B. cereus SMase), which plays a crucial role in bacterial virulence, has emerged as a new therapeutic target for treating opportunistic infections caused by this pathogen. It also shares catalytic domain similarity with human neutral sphingomyelinase 2 (nSMase2), which is implicated in Alzheimer's disease.
View Article and Find Full Text PDFThe steady-state level of plasma membrane ceramide is regulated by neutral sphingomyelinase 2.
J Lipid Res
December 2024
Department of Medicine, Cancer Center at Stony Brook, Stony Brook, NY, USA; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA; Biological Mass Spectrometry Center, Stony Brook University, Stony Brook, NY, USA. Electronic address:
During the last 30 years, an increasing number of cellular functions have been reported to be regulated by the lipid ceramide. The diversity in the ceramide structure, leading to tens of ceramide species and the discrete distribution based on subcellular topology, could explain the wide variety of functions attributed to this bioactive lipid. One of these pools of ceramide resides in the plasma membrane, and several works have suggested that an increase in plasma membrane ceramide (PMCer) in response to stimulation leads to cell death and modulates cell adhesion and migration.
View Article and Find Full Text PDFTargeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization.
Atherosclerosis
October 2024
Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), 08036, Barcelona, Spain; Institut d'Investigacions Biomèdiques IIB Sant Pau, 08041, Barcelona, Spain; CIBER de Enfermedades Cardiovasculares CIBERCV, Institute of Health Carlos III, 28029, Madrid, Spain. Electronic address:
Background And Aims: Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly-Cys of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (LdlrhApoB100 Tg) and determine the potential LDL-related underlying mechanisms.
View Article and Find Full Text PDFDual-Synergistic Nanomodulator Alleviates Exosomal PD-L1 Expression Enabling Exhausted Cytotoxic T Lymphocytes Rejuvenation for Potentiated iRFA-Treated Hepatocellular Carcinoma Immunotherapy.
ACS Nano
November 2024
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, No.87 Dingjiaqiao, Nanjing 224001, P. R. China.
The tumor immunosuppressive microenvironment (TME) induced by incomplete radiofrequency ablation (iRFA) in hepatocellular carcinoma (HCC) is a critical driver of tumor progression and metastasis. Herein, we proposed a therapeutic strategy aimed at remodeling the post-iRFA TME by targeting exosome biogenesis, secretion, and PD-L1 expression, thereby rejuvenating cytotoxic T lymphocyte function to mitigate the progression and metastasis of HCC. Leveraging the versatile properties of polydopamine nanomodulators, we have engineered a tailored delivery platform for GW4869 and amlodipine (AM), enabling precise and tumor-specific release of these therapeutic agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!